An open-label, randomized Phase 3 study evaluating Bristol-Myers Squibb‘s Opdivo versus docetaxel in previously treated patients with advanced, squamous cell non-small cell lung cancer was stopped early because an assessment conducted by the independent Data Monitoring Committee concluded that the study met its endpoint, demonstrating superior overall survival in patients receiving Opdivo compared to the control arm.